The US Food and Drug Administration (FDA) approved the first generics version of Roche Holding AG's blockbuster osteoporosis drug Boniva (ibandronate), marking the next big patent expiry for the ...
Osteoporosis drugs are big sellers, bringing in some $2 billion in 2008 alone. Now one of the newest of those drugs, ibandronate, also known as Boniva, has scored major (and no doubt expensive) ...
HealthDay News — The FDA has approved the first generic versions of the once-monthly osteoporosis drug ibandronate (Boniva, Genentech). The agency granted approvals to market 150 mg generic ...
The Food and Drug Administration said Wednesday it's conducting a safety review of certain bone-building drugs like Fosamax and Boniva to see if they increase the risk of femur fractures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results